Polymeric nanomedicines for the treatment of hepatic diseases

Table 4 Polymer-based NPs as drug carriers for liver disease treatment

Liver disease	Carrier	Delivered drug	Size (nm)	References
HBV infection		HBsAg	143 ± 33	[97]
		siRNA	60	[98]
		Bay41-4109	300–400	[99]
		HBsAg	186.6 ± 3.7	[77]
		DrzBC and DrzBS	123.00 ± 10.98	[100]
		HBsAg	206.3 ± 4.20 and 253.1 ± 7.75	[101]
NAFLD			132.6 ± 13.5	[102]
		IL-22	100	[103]
			50	[104]
	PLGA		210	[105]
	PLGA	Resveratrol	176.1	[106]
	PLGA		160	[107]
		miR-146b mimic	150–350	[108]
			57.7 ± 14.1	[109]
Liver fibrosis			/	[110]
	PLGA		187.6 ± 5.0	[111]
	CS		99 ± 22	[112]
	CS	Collagenase	90 ± 3	[113]
			120	[114]
			70–80	[84]
			632.28 ± 12.15	[115]
			300	[116]
	CS		200–250	[117]
		siRNA	40	[118]
HCC			144.7 ± 6.53	[119]
		Sorafenib	118.3	[120]
			127.96 ± 4.6	[59]
			188.4 ± 6.3	[29]
		Sorafenib	127	[121]
		Sorafenib	278.7 ± 2.2	[122]
			/	[123]
			242 ± 4.6	[124]
	HA	DOX	217.70 ± 0.89	[60]
		DOX	54.27–63.11	[125]
	PLGA		211	[126]
HVGD		shRNA	200–300	[127]
			110.9	[128]
		Tacrolimus	2.30 ± 0.14 μm	[129]
	CS, PLGA	Tacrolimus	345	[130]

HBV, hepatitis B virus; CS, chitosan; HBsAg, hepatitis B surface antigen; PLGA, poly(lactic-co-glycolic acid); mPEG, methoxypolyethylene glycols; NAFLD, nonalcoholic fatty liver disease; Lac-PDMAEMA, lactosylated poly(2-(dimethylamine)ethyl methacrylate)nanoparticle; PAMAM, polyamidoamine; PEG-PCD, poly (ethylene glycol)-block-poly (2-methyl-2-carboxyl-propylene carbonate)-graft-dodecanol; MEO₃MA, tri(ethylene glycol) methylether methacrylate; PFPMA, pentafluorophenyl methacrylate; PAM-PBLG-b-TPGS, poly(amidoamine)-poly(γ-benzyl-l-Glutamate)-b-d-α-tocopheryl polyethylene glycol 1000 succinat; HZ, hydrazide; PLA, polylactic acid; GA, gycyrrhetinic acid; DOX, doxorubicin; PLys, poly(lysine); HA, hyaluronic acid; PBA, phenylboronic acid; Glu, glutamic acid; DA, dopamine; HGPAE, histidine-grafted poly(β-amino ester)

ISSN: 1477-3155